Market Research Logo

Prescription Drugs Market Research Reports & Industry Analysis

In April 2011, the Food and Drug Administration (FDA) announced a new program focused on curbing the abuse and reducing associated risks of prescription opioid painkillers. The Risk Evaluation and Mitigation Strategy (REMS) program focuses primarily on educating doctors about proper pain management, patient selection and improving patient awareness about how to use these drugs safely.

According to the White House, prescription drug abuse has become an epidemic, estimating that in 2007 alone, over 33 million Americans age 12 and older misused opioid painkillers. That same year, drug overdose in the U.S. was one of the leading causes of unintentional injury death, second only to motor vehicle accidents.

One important target of the campaign is the safe disposal of medications. In many cases, doctors have been found to prescribe larger doses of opioids than patients actually use. Many of these pills find their way onto the black market. Additionally, more than half of all non-prescribed painkiller users get their drugs from someone they know. As part of the plan, FDA wants opioid manufacturers to provide prescribing physicians with educational materials, including a medication guide that uses consumer friendly language to explain safe use and disposal.

The drugs targeted by the REMS plan include brand name products known under the generic names hydromorphone, oxycodone, morphine, oxymorphone, methadone, transdermal fentanyl, and transdermal buprenorphine.

...Show More ...Show Less


Filter your search

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Prescription Drugs Industry Research & Market Reports

  • Global Oxytocin Receptor Antagonists Market Research Report 2017

    ... market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Oxytocin Receptor Antagonists basics: ... Read More

  • El Salvador Pharmaceuticals & Healthcare Q1 2018

    ... in a wide range of health infrastructure, resulting in advances to the standard of care in hospitals which are benefitting from the wider availability of state-of-the-art equipment. Pharmaceutical consumption is also being driven by a ... Read More

  • Philippines Pharmaceuticals & Healthcare Q1 2018

    ... country's disease profile will continue to evolve in line with economic and demographic trends and will provide a number of revenue earning opportunities for pharmaceutical firms, a multitude of regulatory issues will create challenges while ... Read More

  • Asia Pharmaceuticals & Healthcare Q1 2018

    ... a greater ability to afford high-value medicines. However, the increased focus on cost-efficiency in these markets will manifest itself through greater pricing pressures on drugmakers, generic substitution policies and rational prescribing initiatives. With regards to ... Read More

  • Azerbaijan Pharmaceuticals & Healthcare Q1 2018

    ... medicine affordability and accessibility, however we note that this is unlikely to be successfully implemented in line with the ambitious timeline. Preference for generic and non-prescription medicines will remain prominent given the low-income nature of ... Read More

  • Norway Pharmaceuticals & Healthcare Q1 2018

    ... High spending per capita on medicine and the growing demand for chronic disease treatment will translate into renewed commercial opportunities for innovative drugmakers. Meanwhile, although the government will continue to promote the development of biomedicine ... Read More

  • Peru Pharmaceuticals & Healthcare Q1 2018

    ... This could derail recent legislative progress between the government and the FP-controlled legislature and, by extension, worsen fears that proposed budgetary plans to inject funds into vital health and other public services may fail to ... Read More

  • Thailand Pharmaceuticals & Healthcare Q1 2018

    ... driven by the country's evolving demographic and epidemiological profile. However, pressure on pharmaceutical prices, low levels of intellectual property enforcement and aggressive cost-containment measures will continue to threaten the operations of multinational drugmakers in Thailand. Read More

  • Medication Management System Market Analysis By Software, By Mode of Delivery (On-premise, Web-based, Cloud-based), By End Use, By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

    ... global medication management system market is expected to reach USD 5.97 billion by 2025 at a CAGR of 20.5%, according to a new report by Grand View Research, Inc. Rise in number of prescriptions globally, ... Read More

  • Georgia Pharmaceuticals & Healthcare Q1 2018

    ... favourable business climate will continue to promote interest in the country's pharmaceutical market. In the meantime, the small domestic industry will be supported by factors such as international funding and government efforts to boost entrepreneurship. Read More

  • Germany Pharmaceuticals & Healthcare Q1 2018

    ... markets. High per capita healthcare and pharmaceutical spend and high utilisation rates will continue to underpin the market's growth, though generic medicines will continue to erode market share of patented drugs in terms of value. Read More

  • Panama Pharmaceuticals & Healthcare Q1 2018

    ... Gradual improvements in the health system management and drug regulation will likely reduce recurrent shortage of medicines over the next few quarters. Meanwhile, the robust business environment (by regional standards), and the strategic role of ... Read More

  • Russia Pharmaceuticals & Healthcare Q1 2018

    ... to the high levels of risk within the market and as such generic medicine sales will be the major beneficiary of this growth. The continued development of the domestic manufacturing industry will provide additional challenges ... Read More

  • Armenia Pharmaceuticals & Healthcare Q1 2018

    ... for medicine sales growth, demand for innovative drugs will remain minimal. Growth in domestic production is increasing with government support. However, there are more attractive markets in the region for use as an export hub. Read More

  • Cambodia Pharmaceuticals & Healthcare Q1 2018

    ... aid and annual increases in government health expenditure will continue to support the gradual development of the health system, which is still subdued. On the downside, increasing political tensions pose risks to the economic outlook. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q1 2018

    ... limited drugmaker opportunities. Reflective of the low purchasing power among the population, the majority of drugs in circulation are generic versions, though the presence of multinationals suggests a growing markets for patented medicines in the ... Read More

  • Hong Kong Pharmaceuticals & Healthcare Q1 2018

    ... for substantial growth. The city's ageing population, increased disease burden, and growing disposable income continue to provide excellent opportunities for foreign pharmaceutical companies. Further supporting the growth of pharmaceutical sales and the expansion of medicine ... Read More

  • Spain Pharmaceuticals & Healthcare Q1 2018

    ... revenue generating opportunities will remain limited. We expect the government to remain committed to fiscal consolidation, targeting the healthcare sector and prescription drug expenditure in particular, as it faces considerable pressure from rising healthcare costs. Read More

  • Pharmaceuticals in Canada: ISIC 2423

    ... at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing ... Read More

  • Global Opioids Drugs Market Research Report 2017

    ... conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). The report firstly introduced the Opioids Drugs basics: definitions, classifications, ... Read More

  • Global Alprazolam Tablets Market Research Report 2017

    ... conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). The report firstly introduced the Alprazolam Tablets basics: definitions, classifications, ... Read More

  • Global Naprosyn Market Research Report 2017

    ... on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China). The report firstly introduced the Naprosyn basics: definitions, classifications, applications and market ... Read More

  • Croatia Pharmaceuticals & Healthcare Q1 2018

    ... the continued economic recovery. The market will displaytrends common with neighbouring markets, notably increased generic substitution rhetoric. However,increased demand for high-value drugs will partially offset this headwind and will boost sales growth overthe long term. Read More

  • South Korea Pharmaceuticals & Healthcare Q1 2018

    ... The government's support for the pharmaceutical industry, as reflected by therecent announcement of new legislation to improve medical information transparency and tacklecorruption, bodes well for South Korea's long-term potential as a proposition for pharmaceutical firms. Read More

  • Brazil Pharmaceuticals & Healthcare Q1 2018

    ... access to basic healthcare underpin the importance of Brazil'spharmaceutical market. However, challenging pricing and reimbursement conditions for high costmedicines means that the market will continue to offer most potential for local drug makers supplyingessential medicines. Read More

2 4 5 6 7 8 9 10